RC118 for solid cancers with Claudin 18.2 on tumor cells
Part of Cancer clinical trials.
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and are age 18 to 75
- You have advanced cancer that can’t be removed or has spread, and standard treatment is not working or isn’t tolerated
- Your body is in relatively good shape (ECOG 0 to 1) and you’re expected to live more than 12 weeks
- Your tumor must be Claudin 18.2 positive on the cell surface, and you’ll provide fresh or saved tumor tissue for testing
- You must have at least one measurable tumor spot on CT or MRI
- Your blood and organ tests (bone marrow, liver, kidneys, and clotting) must meet the study’s lab limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ARC101 for people with advanced solid tumors that are Claudin-6 positive. It aims to see if the drug is safe and can help shrink tumors or slow their growth.
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
This study tests a new treatment using your own immune cells (called CAR-T and CAR-DC) that are engineered to attack cancer cells with a specific protein (Claudin18.2). It is for people with advanced colorectal cancer who have exhausted standard treatments.
This study tests a new drug called RC288 to treat solid tumors (cancers that form lumps). Researchers want to see if it's safe and how well it works for people whose cancer hasn't responded to other treatments or has returned.
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
This trial tests an investigational drug called TJ037130 in people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment is available. The drug targets a protein called Claudin 6 on tumor cells and may help your immune system fight the cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.